Estimation of adipogenesis in SCE tretment.

<p>(A) Cellular morphology. (Panels a–f) Micrographs (×10) showing (a) MDI negative, (b) MDI positive (vehicle control) (c) differentiating 3T3-L1 adipocytes treated for 8 days with rosiglitazone (10 µM), and (d–f) various concentrations of SCE (10, 25 and 50 µg/mL, respectively). DMSO (0.1%, vehicle) in differentiation media served as the vehicle control group i.e MDI positive. (B) Glycerol-3-phosphate dehydrogenase activity in various groups (MDI positive, rosiglitazone at 10 µM) and various concentrations of SCE (10, 25 and 50 µg/mL, respectively). (C) Diacyl glycerol -3 phosphate activity in various groups (MDI positive, rosiglitazone at 10 µM) and various concentrations of SCE (10, 25 and 50 µg/mL, respectively). (D) The triglyceride content in various groups (MDI positive, rosiglitazone at 10 µM) and various concentrations of SCE (10, 25 and 50 µg/mL, respectively). (E) Adiponectin level in various groups (MDI positive, rosiglitazone at 10 µM) and various concentrations of SCE (10, 25 and 50 µg/mL, respectively). Results are normalised to 100 based on control readings. Data are expressed as the means ± SD; n = 3. *Represents groups that differ significantly from the MDI positive (vehicle control) group (P≤0.05).